Strategy of Hope: Small, Rapid Viral-Load Trials

var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); ion" CONTENT="At the New Directions in Antiviral Chemotherapy conference in November, Dr. Douglas Richman--a leading AIDS researcher-- spoke of the value of small, rapid trials to look for antiviral activity in people. In a two-week study, you can show whether a drug works or doesn t work, said Richman. He also spoke of evidence tha"> Strategy of Hope: Small, Rapid Viral-Load Trials < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); > < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); >

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Strategy of Hope: Small, Rapid Viral-Load Trials

AIDS Treatment News (11/18/94) No. 211, P. 1
James, John S.

At the New Directions in Antiviral Chemotherapy conference in November, Dr. Douglas Richman--a leading AIDS researcher-- spoke of the value of small, rapid trials to look for antiviral activity in people. "In a two-week study, you can show whether a drug works or doesn't work," said Richman. He also spoke of evidence that if the viral load--as measured by HIV RNA--could be kept down, the immune system could spontaneously recover. These ideas are gaining strength in the professional community, he said. There is debate in the issue because some say that it is not proven that reducing and keeping down the plasma HIV RNA will benefit the patient. The same people base their own thoughts and plans on the assumption that lowering the viral load is the central goal. Richman and most other professional researchers only speak of the drugs being manufactured by pharmaceutical companies: natural products, traditional medicines used in cultures around the world, and readily available pre ion drugs are not considered for potential HIV treatments. HIV resistance to antiviral drugs is also a problem. Small, rapid trials allow many leads to be followed up quickly, and new combinations to be developed rapidly.

941227
AD942314

Copyright © 1994 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .